The FSHD muscle–blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy

Abstract Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent, incurable skeletal myopathy. Clinical trials for FSHD are hindered by heterogeneous biomarkers poorly associated with clinical severity, requiring invasive muscle biopsy. Macroscopically, FSHD presents with slow fatty replacement of muscle, rapidly accelerated by inflammation. Mis-expression of the transcription factor DUX4 is currently accepted to underlie pathogenesis, and mechanisms including PAX7 target gene repression have been proposed. Here, we performed RNA-sequencing on MRI-guided inflamed and isogenic non-inflamed muscle biopsies from the same clinically characterized FSHD patients (n = 24), alongside isogenic peripheral blood mononucleated cells from a subset of patients (n = 13) and unaffected controls (n = 11). Multivariate models were employed to evaluate the clinical associations of five published FSHD transcriptomic biomarkers. We demonstrated that PAX7 target gene repression can discriminate control, inflamed and non-inflamed FSHD muscle independently of age and sex (P < 0.013), while the discriminatory power of DUX4 target genes was limited to distinguishing FSHD muscle from control. Importantly, the level of PAX7 target gene repression in non-inflamed muscle associated with clinical assessments of FSHD severity (P = 0.04). DUX4 target gene biomarkers in FSHD muscle showed associations with lower limb fat fraction and D4Z4 array length but not clinical assessment. Lastly, PAX7 target gene repression in FSHD muscle correlated with the level in isogenic peripheral blood mononucleated cells (P = 0.002). A refined PAX7 target gene biomarker comprising 143/601 PAX7 target genes computed in peripheral blood (the FSHD muscle–blood biomarker) associated with clinical severity in FSHD patients (P < 0.036). Our new circulating biomarker validates as a classifier of clinical severity in an independent data set of 54 FSHD patient and 29 matched control blood samples, with improved power in older patients (P = 0.03). In summary, we present the minimally invasive FSHD muscle–blood biomarker of FSHD clinical severity valid in patient muscle and blood, of potential use in routine disease monitoring and clinical trials.

[1]  S. Tapscott,et al.  Facioscapulohumeral muscular dystrophy: the road to targeted therapies , 2023, Nature Reviews Neurology.

[2]  C. Banerji,et al.  An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy , 2022, bioRxiv.

[3]  S. Tapscott,et al.  Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers , 2022, Scientific Reports.

[4]  K. Mamchaoui,et al.  Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target , 2022, Redox biology.

[5]  S. Tapscott,et al.  Elevated plasma complement components in facioscapulohumeral dystrophy. , 2021, Human molecular genetics.

[6]  N. Glaichenhaus,et al.  Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy , 2021, Journal of neuromuscular diseases.

[7]  C. Banerji,et al.  Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7 , 2021, EMBO molecular medicine.

[8]  E. Ricci,et al.  Proteomics of Muscle Microdialysates Identifies Potential Circulating Biomarkers in Facioscapulohumeral Muscular Dystrophy , 2020, International journal of molecular sciences.

[9]  M. Kyba,et al.  Meeting report: the 2020 FSHD International Research Congress , 2020, Skeletal Muscle.

[10]  A. Connolly,et al.  Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy , 2020, Journal of personalized medicine.

[11]  S. Tapscott,et al.  Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients , 2020, Scientific Reports.

[12]  S. Bozkurt,et al.  The ratios of estradiol and progesterone to testosterone influence the severity of facioscapulohumeral muscular dystrophy , 2020 .

[13]  D. Henderson,et al.  Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity , 2020, Human molecular genetics.

[14]  Y. Hayashi,et al.  Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy , 2020, Neurology.

[15]  C. Banerji.  PAX7 target gene repression associates with FSHD progression and pathology over one year. , 2020, Human molecular genetics.

[16]  L. C. López,et al.  OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION , 2020, Series of biological and medical.

[17]  C. Banerji,et al.  DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation , 2020, Human molecular genetics.

[18]  C. Banerji,et al.  Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of self-reported symptoms , 2020, Neuromuscular Disorders.

[19]  B. V. van Engelen,et al.  Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy , 2020, Clinical genetics.

[20]  S. Tapscott,et al.  Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies. , 2020, Human molecular genetics.

[21]  Peter L Jones,et al.  The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy. , 2019, Annual review of genomics and human genetics.

[22]  C. Banerji,et al.  PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level , 2019, Human molecular genetics.

[23]  A. Mortazavi,et al.  Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei , 2018, bioRxiv.

[24]  S. Tapscott,et al.  MRI‐informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD , 2018, Human molecular genetics.

[25]  B. Engelen,et al.  Lifetime endogenous estrogen exposure and disease severity in female patients with facioscapulohumeral muscular dystrophy , 2018, Neuromuscular Disorders.

[26]  Simone Severini,et al.  PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle , 2017, Nature Communications.

[27]  M. Kyba,et al.  The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain , 2017, Journal of Cell Science.

[28]  M. Crescenzi,et al.  Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity , 2017, The Journal of clinical investigation.

[29]  B. den Hamer,et al.  DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis , 2016, Development.

[30]  B. Chadwick,et al.  Influence of Repressive Histone and DNA Methylation upon D4Z4 Transcription in Non-Myogenic Cells , 2016, PloS one.

[31]  S. Tapscott,et al.  Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy. , 2016, American journal of human genetics.

[32]  F. Sera,et al.  A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes , 2016, Journal of Neurology.

[33]  Michael Kyba,et al.  DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes , 2016, Nucleic acids research.

[34]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[35]  Zizhen Yao,et al.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. , 2014, Human molecular genetics.

[36]  A. Verbeek,et al.  Population-based incidence and prevalence of facioscapulohumeral dystrophy , 2014, Neurology.

[37]  J. Blake,et al.  Pax genes: regulators of lineage specification and progenitor cell maintenance , 2014, Development.

[38]  Stephen J. Tapscott,et al.  DUX4 Binding to Retroelements Creates Promoters That Are Active in FSHD Muscle and Testis , 2013, PLoS genetics.

[39]  M. Kyba,et al.  Expression of the human FSHD-linked DUX4 gene induces neurogenesis during differentiation of murine embryonic stem cells. , 2013, Stem cells and development.

[40]  Daniel G. Miller,et al.  Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2 , 2012, Nature Genetics.

[41]  O. King,et al.  Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers , 2012, Proceedings of the National Academy of Sciences.

[42]  J. Pincemail,et al.  Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. , 2012, Free radical biology & medicine.

[43]  M. García-Castro,et al.  Pax7 Lineage Contributions to the Mammalian Neural Crest , 2012, PloS one.

[44]  Tiziana Cubeddu,et al.  Different Molecular Signatures in Magnetic Resonance Imaging-Staged Facioscapulohumeral Muscular Dystrophy Muscles , 2012, PloS one.

[45]  Abraham P. Fong,et al.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. , 2012, Developmental cell.

[46]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[47]  Daniel G. Miller,et al.  Facioscapulohumeral Dystrophy: Incomplete Suppression of a Retrotransposed Gene , 2010, PLoS genetics.

[48]  Daniel G. Miller,et al.  A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy , 2010, Science.

[49]  Gabriele Siciliano,et al.  A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score , 2010, Muscle & nerve.

[50]  M. Kyba,et al.  An isogenetic myoblast expression screen identifies DUX4‐mediated FSHD‐associated molecular pathologies , 2008, The EMBO journal.

[51]  H. Qian,et al.  DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1 , 2007, Proceedings of the National Academy of Sciences.

[52]  B. Vernus,et al.  Myostatin in the Pathophysiology of Skeletal Muscle , 2007, Current genomics.

[53]  A. Rosa,et al.  The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein , 2007, Neuromuscular Disorders.

[54]  S. Welle,et al.  Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy , 2007, Neurology.

[55]  B. Shneiderman,et al.  Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. , 2006, Brain : a journal of neurology.

[56]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  H. Ding,et al.  Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. , 1999, Gene.

[58]  E. Wagner,et al.  Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5 BSAP , 1994, Cell.

[59]  J E Hewitt,et al.  Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. , 1994, Human molecular genetics.

[60]  C. Wijmenga,et al.  Molecular genetics of facioscapulohumeral muscular dystrophy , 1993, Neuromuscular Disorders.

[61]  J E Hewitt,et al.  FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. , 1993, Human molecular genetics.

[62]  S. Tapscott,et al.  Multiplex Screen of Serum Biomarkers in Facioscapulohumeral Muscular Dystrophy. , 2014, Journal of neuromuscular diseases.

[63]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..